Edition:
United Kingdom

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

631.90INR
5:00am GMT
Change (% chg)

Rs12.15 (+1.96%)
Prev Close
Rs619.75
Open
Rs625.00
Day's High
Rs639.85
Day's Low
Rs624.30
Volume
4,276,837
Avg. Vol
3,357,807
52-wk High
Rs657.50
52-wk Low
Rs295.03

Select another date:

Wed, Feb 21 2018

BRIEF-India's Biocon ‍Says U.S. FDA Completed Pre-Approval Inspection At Malaysia Unit ​

* ‍U.S. FDA COMPLETED PRE-APPROVAL INSPECTION AT MALAYSIA FACILITY AND ISSUED FORM 483 WITH 6 OBSERVATIONS​ Source text - http://bit.ly/2EUL56I Further company coverage:

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE

India's Biocon Q3 profit plunges 46 pct

Jan 24 Biocon Ltd, India's biggest biotechnology firm, posted a 46 percent fall in third-quarter profit on Wednesday hurt by an increase in interest and depreciation costs related to its Malaysia operations.

BRIEF-India's Biocon Dec-Qtr Consol Profit Down About 46 pct

* DEC QUARTER CONSOL PROFIT 919 MILLION RUPEES VERSUS 1.71 BILLION RUPEES LAST YEAR

BRIEF-Biocon Announces Exclusive Global Collaboration With Sandoz On Next-Generation Biosimilars

* ANNOUNCES EXCLUSIVE GLOBAL COLLABORATION WITH SANDOZ ON NEXT-GENERATION BIOSIMILARS'

BRIEF-Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil

* CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS

BRIEF-Biocon Says Has Paid Facility Fee For Its API Facility To U.S. FDA

* CLARIFIES ON NEWS ITEM REGARDING CO'S NAME ON FDA LIST FOR NOT PAYING FACILITY FEE

BRIEF-India's Biocon To Transfer Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India

* INDIA'S BIOCON SAYS TO TRANSFER BIOSIMILAR BUSINESS THROUGH SLUMP SALE AS 'GOING CONCERN' TO BIOCON BIOLOGICS INDIA - EXCHANGES

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

Select another date: